Investor Centre

Media

  • Video,camera,with,blur,background,for,journalist,interview,broadcasting,reporter

    The Australian: Racura Oncology Stock Gains On US FDA Milestone

    The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Racura’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Racura to be eligible for a Priority Review Voucher (PRV). Racura’s Executive Director, Dr Peter Smith, explains in…

    Cal Icon
  • Pile,of,newspapers,on,white,background

    Proactive: Racura Oncology At 12-Month High On Promising Preclinical Results For Drug Combination In Multiple Myeloma Treatment

    Proactive reports that Racura has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma. Racura CEO Dr Daniel Tillett commented: “The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib,…

    Cal Icon
  • Video,camera,with,blur,background,for,journalist,interview,broadcasting,reporter

    Proactive: Racura Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220

    The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Racura CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial advantage that the ODD will bring to bisantrene. Read the full report here.

    Cal Icon
  • Video,camera,with,blur,background,for,journalist,interview,broadcasting,reporter

    Sharewise Webinar With CEO Dr Daniel Tillett

    In this webinar hosted by Sharewise, Racura Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability to deliver both anti-cancer and cardioprotection, and its current stage of clinical development. He also answers a range of questions from…

    Cal Icon
    |
  • Video,camera,with,blur,background,for,journalist,interview,broadcasting,reporter

    Demystifying Clinical Trials & Approval Processes

    In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Racura Oncology’s journey through the drug development process. Dr Tillett shared insights into the company’s unique market position and potential growth opportunities with lead drug, bisantrene. You can watch Daniel’s interview…

    Cal Icon
    |
  • Video,camera,with,blur,background,for,journalist,interview,broadcasting,reporter

    The “Racura” To Beat Cancer

    Racura CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year. Dr Tillett says one of the most notable achievements in the quarter was the news that Racura’s RC220 bisantrene formulation met all cGMP…

    Cal Icon
  • Pile,of,newspapers,on,white,background

    Racura CEO Discusses Benefits Of Resurrecting Abandoned Drugs With Stockhead

    Racura CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to whether a drug makes it to market or not. He further lists examples of companies that succeeded in drug repurposing. Read the full article here

    Cal Icon
  • Video,camera,with,blur,background,for,journalist,interview,broadcasting,reporter

    WTF With Racura Oncology: Changing The Chemo Game – Stockhead

    Racura Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health as patients go through cancer treatment.  The damage to the heart is one of the most serious side effects of cancer treatment, as the heart…

    Cal Icon
    |
  • Rac Shareholder Options Qa Image

    Shareholder Options Q&A

    We thank all our shareholders for their strong interest in the Racura Oncology Bonus Options and Piggyback Options Offer. We have been receiving many questions in relation to these options, so to help we have prepared a document answering the most frequently asked questions. Please CLICK HERE  to access the Q&A document that includes explanations on how…

    Cal Icon
Racura Oncology
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.